Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Regulation Policy Approvals

News We’re Watching – 20 January

  • News

Executive Summary

This new Medtech Insight feature compiles news briefs on a range of US regulatory and legal happenings. This week: Congressional criticism of ClinicalTrials.gov, new radiation device performance standards, clearance of a new sepsis test and two new device classifications.

You may also be interested in...



News We're Watching – 27 January

This feature compiles news briefs on a range of US regulatory and legal happenings. This week: Medtronic seeks HeartWare batteries; companies sign health equity pledge; insulin dosing app cleared; recall on field decontamination kits; and the renewal of an FDA panel. 

Product Liability Missteps Top List Of Worst Legal Verdicts Of 2022

A recent webinar ranking last year’s best and worst legal verdicts said that product liability cases involving pelvic mesh and artificial lenses were the very worst. 

J&J Subsidiary Pays $9.75M To Resolve Kickback Allegations

DePuy Synthes reportedly provided a Massachusetts surgeon with more than $100,000 in free implants and tools.

Table

View full table

Topics

Tags:
Regulation Policy Approvals
Latest Headlines

Philips Implements Plan To Address FDA Concerns Following Harsh Inspection Report

News We're Watching – 27 January

Product Liability Missteps Top List Of Worst Legal Verdicts Of 2022

EMA Expert Advice Pilot Could Be ‘Vital Source Of Guidance’ For SMEs

See All
UsernamePublicRestriction

Register

MT147559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By